ISRCTN12265152 https://doi.org/10.1186/ISRCTN12265152

Pilot phase I, safety and pharmacokinetic study in healthy participants

Submission date 18/11/2025	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 18/11/2025	**Overall study status** Deferred	
Last Edited 18/11/2025	**Condition category** Other	

Plain English summary of protocol
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Public, Scientific

Contact name
Mr James Murray

Contact details
Heath Technical Business Park
Runcorn
United Kingdom
WA7 4QX
+44 (0)1928518856
james.murray@orbia.com

Type(s)
Principal investigator

Contact name
Dr Caroline Baxter

Contact details
Medicines Evaluation Unit
Langley Building, Southmoor Road
Manchester
United Kingdom

M23 9QZ
+44 (0)161 946 4050
cbaxter@meu.org.uk

Additional identifiers

Integrated Research Application System (IRAS)
1012318

Study information

Scientific Title
Pilot phase I, safety and pharmacokinetic study in healthy participants

Acronym
KZ-01

Study objectives
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 22/09/2025, North West - Greater Manchester Central Research Ethics Committee (2 Redman Place, London, E20 1JQ, United Kingdom; N/A; gmcentral.rec@hra.nhs.uk), ref: 25/NW/0216

Primary study design
Interventional

Study design
Pilot Phase I, safety and pharmacokinetic study in healthy participants

Study type(s)
Safety

Health condition(s) or problem(s) studied
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase
Phase I

Drug/device/biological/vaccine name(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date
31/12/2025

Eligibility

Key inclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)
Healthy volunteer

Healthy volunteers allowed
Yes

Age group
Mixed

Sex
All

Total final enrolment
12

Key exclusion criteria
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
01/10/2025

Date of final enrolment
05/11/2025

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
Medicines Evaluation Unit Limited
The Langley Building
Southmoor Road
Wythenshawe
Manchester
England
M23 9QZ

Sponsor information

Organisation
Mexichem UK Ltd

Funder(s)

Funder type
Not defined

Funder Name
Mexichem UK Ltd

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Data sharing statement to be made available at a later date